Blood Screening Market Overview, Analysis And Demand By 2034
Crafted for informed planning, this report explores the forces reshaping the blood screening market and what they mean for business leaders.
How Large Will The Blood Screening Market Be By 2025?
The blood screening market size has grown strongly in recent years. It will grow from $3.15 billion in 2024 to $3.44 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased blood transfusion requirements, rising prevalence of transmissible diseases, government regulations and standards, increasing blood donations and collection, global health concerns and pandemics.
The blood screening market size is expected to see rapid growth in the next few years. It will grow to $5.33 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to healthcare infrastructure development, public health awareness programs, advancements in infectious disease diagnostics, global health concerns and pandemic preparedness. Major trends in the forecast period include rise in infectious diseases, automation and efficiency, rising blood transfusion demands, focus on transfusion safety, research in pathogen detection.
Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9047&type=smp
What Are Key Factors Driving The Demand In The Global Blood Screening Market?
The increasing prevalence of infectious diseases is expected to propel the growth of the blood screening market going forward. Blood is commonly analyzed for symptoms of illness by looking for a specific antibody generated against the infectious agent, which aids the medical practitioner in treating infectious diseases and preventing further transmission of infection in patients and disease spread from one to one. For instance, in June 2022, according to the National Center for Biotechnology Information, a US-based government agency, in two decades the prevalence of infectious diseases in outpatient care has increased almost three times, from 8 to 26 per 1,000. Therefore, the increase in the prevalence of infectious diseases is driving the growth of the blood screening market.
Comparative Analysis Of Leading Blood Screening Market Segments
The blood screeningmarket covered in this report is segmented –
1) By Product: Reagents And Kits; Instruments; Software And Services
2) By Technology: Nucleic Acid Testing; Enzyme-Linked Immunosorbent Assay (ELISA); Rapid Tests; Western Blot Assays; Next-Generation Sequencing (NGS)
3) By End User: Blood Banks; Diagnostic Centers And Pathology Labs; Hospitals; Clinics; Ambulatory Surgical Centers (ASCs)
Subsegments:
1) By Reagents And Kits: Diagnostic Reagents; Testing Kits
2) By Instruments: Automated Analyzers; Manual Testing Equipment
3) By Software And Services: Laboratory Information Management Systems (LIMS); Data Analysis Software; Support And Consulting Services
What Are The Key Trends Shaping The Blood Screening Industry?
Major companies operating in the blood screening market are developing technologies such as liquid biopsy to enhance early cancer detection, improve treatment monitoring, and enable personalized medicine approaches. A liquid biopsy is a minimally invasive test that analyzes blood or other body fluids to detect cancer cells or genetic material from tumors. For instance, in November 2023, Guardant Health, Inc., a US-based biotechnology company, launched Shield blood-based screening tests. The Shield test analyzes cell-free DNA (cfDNA) in the bloodstream, which can indicate the presence of colorectal tumors or precancerous growths. It specifically looks for alterations in DNA fragments that are released into the blood from cancer cells.
Who Are The Prominent Players In The Blood Screening Business?
Major companies operating in the blood screening market include Abbott Laboratories, Grifols S.A., Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, GE Healthcare, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, Natera Inc., GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Accelerate Diagnostics Inc., Cepheid Inc., T2 Biosystems Inc., Haemonetics Corporation, HTG Molecular Diagnostics Inc., Verax Biomedical Inc.
View the full blood screening market report here:
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report
Which Region Is Expected To Lead The Blood Screening Market By 2025?
North America was the largest region in the blood screening market in 2024. The regions covered in the blood screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment